Amazon just set the price floor for GLP-1s

Amazon One Medical launched a national GLP-1 program at $149/month.

Amazon rolled out a coast-to-coast weight management program through One Medical and Amazon Pharmacy on April 21.

Cash-pay starts at $149/month for branded Wegovy or Foundayo. Insurance pricing drops as low as $25/month.

Same-day delivery covers nearly 3,000 cities today, expanding to 4,500 by year end. On-demand video care starts at $49 for non-One Medical patients.

This is the new price floor. If your pricing page is still anchored at $250-$400 for the same molecule, your value prop has to do real work to justify the gap.

Hims added the full FDA-approved GLP-1 catalog on April 23.

Eli Lilly's Zepbound, Mounjaro, and oral Foundayo now route from Hims providers directly to LillyDirect pharmacy. Wegovy and Ozempic injectables are also live on the platform.

JPMorgan initiated coverage on April 24 with an Overweight rating and a $35 price target, calling the Novo Nordisk partnership a turning point for the weight loss business.

The big three are converging on a "we have everything FDA-approved" pitch. Brands without the Lilly or Novo plumbing are now pitching narrower, and need a different reason to exist.

Ro cut GLP-1 subscription prices through its Body Membership program.

Ro's annual prepaid plan brings effective monthly pricing to around $74. First-month rates start near $39, with up to $900 per year in savings on coaching, labs, and branded therapy access.

The pricing band across category leaders is collapsing fast. Hims around $79, Ro between $39 and $74, Amazon at $149 cash or $25 insured.

If your effective monthly sits well above that band on the high side, "premium" is a story you have to keep proving every refill. Otherwise patients leave for cheaper.

FDA opened a path to reverse the peptide ban.

On April 15, FDA took its first formal step toward letting compounding pharmacies produce seven peptides previously restricted. The Pharmacy Compounding Advisory Committee meets on July 23-24 to weigh in.

If the ban gets walked back, the next wave of cross-sell category for telehealth (BPC-157, Sermorelin, and others) reopens. That changes the catalog math for any brand betting on longevity or recovery as the second product after GLP-1.

Don't bet on it yet. But build flexibility into your post-purchase flow now so a new category drops in cleanly when it lands.

Amazon just set the price floor for telehealth GLP-1. The brands sweating most aren't Hims or Ro.

Last Tuesday Amazon One Medical announced national $149 GLP-1 with same-day delivery in 3,000 cities. Hims and Ro have the scale and the Novo or Lilly partnerships to adapt.

The brands in real trouble are the 200 mid-tier telehealth shops selling the same Wegovy at $250-$400. If your pricing was already 2x the new floor, your justification just got 2x harder.

And the answer is not to drop price. The answer is to redesign what a patient is paying you for.

1. Provider relationship is the asset Amazon can't replicate at scale.

Amazon has 4,500 cities and same-day delivery. What it does not have is a named provider who remembers your patient.

Most mid-market telehealth brands already have that, then bury it under generic templated emails. The fix is upstream of copy.

Make sure every patient knows their provider's name by week one. Use it in every clinical touchpoint after that.

The "note from your provider" plain text email outperforms designed templates on lapsed and cold re-engagement specifically because it feels human. That signal is your moat against retail.

2. Cross-sell architecture is the new ceiling.

When Amazon prices the first product at $149, the only way the unit economics work is to make the second order the real margin event.

Most brands trigger cross-sell at month 6 or later. The actual window is weeks 6 to 12, when the patient is settled, seeing some result, and starting to ask "what else."

Build the educational layer for adjacent treatments early in onboarding. NAD+ for energy. Peptides if your formulary supports them. HRT for the right cohorts.

Frame every offer as a clinical recommendation from the provider, never as an ecommerce upsell. "Patients on GLP-1 often benefit from..." beats "Add to cart" every time.

3. Niche specialization beats horizontal coverage.

Amazon will sell GLP-1 to anyone with a One Medical login. Hims, Ro, and Walgreens are racing to be the everything store for telehealth.

That leaves the niche layer wide open. The GLP-1 brand for women in perimenopause. The peptide brand for athletes over 40. The recovery program for postpartum patients.

Niche is not just a marketing angle. It is the structural reason a patient stays when a $25 insured option pops up on Amazon.

If you cannot answer "who is this for" in one sentence and "why is the experience designed for that person" in two more, your retention is borrowed against the next price cut.

The takeaway.

Amazon owns the floor. The ceiling is everything that happens between shipments.

Your provider relationship, your cross-sell architecture, and your niche depth are not nice-to-haves anymore. They are the only line items separating you from being a more expensive version of the same drug.

The pricing band is collapsing.

Ro at $39 first month. Hims around $79. Amazon at $149 cash or $25 insured. That is the band.

If your effective monthly is north of $200 with no clear differentiation built into the patient experience, you are not premium, you are misaligned. Premium is earned at every touchpoint or it stops being premium.

Foundayo just changed the onboarding playbook.

Lilly's oral GLP-1 is now on Hims and Amazon. Patients who picked your brand specifically because injections felt like a barrier are about to get a pill option from a bigger competitor.

Your onboarding email at day 3 should already address why your specific flow still beats a generic pill prescription. If the answer is "we have a provider who knows your file," say that explicitly.

Peptides are the next category to plan for.

FDA's April 15 step toward reversing the peptide ban opens BPC-157, Sermorelin, and five others in the medium term. Smart brands are mapping where these treatments fit before final approval lands.

The ones who already know which peptide pairs with which patient cohort will roll the catalog in 30 days when policy clears. The ones still figuring it out lose another quarter of LTV.

Pull your cross-sell triggers. Look at when each one fires for the first time after a patient's first GLP-1 shipment.

If your first cross-sell touch lands later than week 6, you are missing the highest-intent window. Patients in weeks 6 to 12 are settled, seeing early results, and actively asking "what else helps."

Build one new email this week that triggers off behavioral signal at week 6, not calendar time. Suggested signal: opened at least one provider-voice email AND filled a refill order on time.

Frame the email as a provider note ("noticed patients on your protocol often benefit from..."), not a promo. We see these convert at 3-5x the rate of calendar-triggered cross-sells, and they take under an hour to spec.

If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz

Reply to this with your biggest retention challenge. I read and respond to every single one.